Hepatic Oncology最新文献

{"title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma.","authors":"Stephanie Klein, Jean-François Dufour","doi":"10.2217/hep-2017-0013","DOIUrl":"https://doi.org/10.2217/hep-2017-0013","url":null,"abstract":"Hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease is becoming more common globally. The incidence of HCC due to nonalcoholic steatohepatitis in comparison to other etiologies is increasing. This is due to the pandemic of obesity and diabetes mellitus, two important risk factors for HCC. HCC arising in this context occurs in about 40% of the cases in a liver which is not yet cirrhotic. This has implications regarding the population which should be enrolled in an HCC surveillance program and regarding the treatment options. Surgery is more frequently contemplated in patients with HCC and no cirrhosis. However, patients with nonalcoholic steatohepatitis-induced HCC have frequent co-morbidities which have to be taken into account when developing a management strategy. Interestingly, these patients are frequently on medications which have been suggested to decrease the risk to develop HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 3","pages":"83-98"},"PeriodicalIF":5.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36465623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The status of transarterial chemoembolization treatment in the era of precision oncology.","authors":"Valerie Fako,&nbsp;Xin Wei Wang","doi":"10.2217/hep-2017-0009","DOIUrl":"https://doi.org/10.2217/hep-2017-0009","url":null,"abstract":"<p><p>Transarterial chemoembolization (TACE) is the gold standard of therapy for patients with unresectable intermediate stage hepatocellular carcinoma (HCC), and is also commonly used as postresection adjuvant therapy in Asia. The delivery of TACE is highly variable from center to center, and clinical decision making for patients is based primarily on tumor staging guidelines, with very little focus on individualized tumor features. This review will discuss recent efforts for improving patient outcomes with TACE treatment through personalized medicine advances, including ongoing clinical trials investigating the combination of targeted therapy with TACE and the discovery of prognostic biomarkers for predicting TACE response.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 2","pages":"55-63"},"PeriodicalIF":5.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35582631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?","authors":"Isabel Fabregat,&nbsp;Gianluigi Giannelli","doi":"10.2217/hep-2017-0012","DOIUrl":"10.2217/hep-2017-0012","url":null,"abstract":"","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 2","pages":"35-38"},"PeriodicalIF":5.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.","authors":"Petros Giovanis,&nbsp;Graziano Pianezze,&nbsp;Valter Vincenzi,&nbsp;Carla Manuppelli,&nbsp;Massimo Boaretto,&nbsp;Davide Pastorelli","doi":"10.2217/hep-2016-0011","DOIUrl":"https://doi.org/10.2217/hep-2016-0011","url":null,"abstract":"<p><strong>Aim: </strong>We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP).</p><p><strong>Materials & methods: </strong>CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks.</p><p><strong>Results: </strong>Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months.</p><p><strong>Conclusion: </strong>Treatment with sorafenib changed CEC levels in HCC patients.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 2","pages":"39-43"},"PeriodicalIF":5.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma.","authors":"Giammaria Fiorentini,&nbsp;Andrea Mambrini,&nbsp;Donatella Sarti,&nbsp;Maurizio Cantore,&nbsp;Luca Mulazzani,&nbsp;Gian Maria Mattioli,&nbsp;Stefano Guadagni","doi":"10.2217/hep-2017-0001","DOIUrl":"https://doi.org/10.2217/hep-2017-0001","url":null,"abstract":"<p><strong>Aim: </strong>The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectable cholangiocarcinoma.</p><p><strong>Patients & methods: </strong>In this retrospective observational study, 145 cholangiocarcinoma patients were treated with Epirubicin-Cisplatin as IACHT associated with Capecitabine or 5-fluorouracil as SCHT. Maintenance was performed with gemcitabine-based schedule. Toxicity was assessed with NCI-CTCAE and tumor response with RECIST 1.1.</p><p><strong>Results: </strong>Tumor response was complete in 1%, partial in 20%, stable disease in 48% and progression in 31% of patients (3 months after therapy). The most frequent adverse events were: anemia (24%), nausea and vomiting (33%), alopecia (60%).</p><p><strong>Conclusion: </strong>Cholangiocarcinoma patients may benefit from IAHCT-SCHT. Maintenance may prolong clinical benefits. ClinicalTrials.gov registry Identifier: NCT01920503.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 2","pages":"45-53"},"PeriodicalIF":5.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast growth factor 19, a double-edged sword.","authors":"Peter Lm Jansen","doi":"10.2217/hep-2017-0008","DOIUrl":"https://doi.org/10.2217/hep-2017-0008","url":null,"abstract":"The liver is specialized in handling bile salts. Bile salts are needed for bile formation and the digestion of fats in the intestine. It is this digestive function that makes bile salts cytotoxic. At concentrations in the millimolar range bile salts act as detergents and at lower concentrations they are proapoptotic, proinflammatory and cause necrosis [1] . Therefore, when during evolution changes in nutritional habits demanded the digestion of fats as a source of calories, bile salts with detergent properties were needed and mechanisms evolved to limit the toxicity of bile salts in the liver. The farnesoid X-receptor (FXR) and FGF19 play a critical role as protectors of the liver. The","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 1","pages":"1-4"},"PeriodicalIF":5.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring liver physiology, pathology, TGF-β, EMT, stemness and new developments in liver cancer.","authors":"Isabel Fabregat","doi":"10.2217/hep-2017-0007","DOIUrl":"https://doi.org/10.2217/hep-2017-0007","url":null,"abstract":"<p><p><b>Isabel Fabregat speaks to Roshaine Wijayatunga, Managing Commissioning Editor.</b> Isabel Fabregat, PhD, is Senior Investigator, Head of the group \"TGF-β and cancer\", at the Bellvitge Biomedical Research Institute (IDIBELL) and Associate Professor in the School of Medicine and Health Sciences at the University of Barcelona. She is the President of the Spanish Society for Cell Biology since 2011, she was member of the Executive Board of the Spanish Branch of the European Tissue Culture Society and she is currently member of the Spanish Society for the Study of the Liver, and the International Liver Cancer Association, among others. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by TGF-β in liver cells that can explain its different, and sometimes opposite, functions in liver pathologies, in particular fibrosis and hepatocarcinogenesis. Cross-talk between TGF-β and other pathways, in particular EGFR signaling, is also one of the current interests of the lab. From October 2012 she has coordinated an Initial Training Network - Marie Curie European Action that under the acronym of 'IT-LIVER' (Inhibiting TGF-β in Liver Diseases) integrates different European academic groups and small enterprises to develop a multidisciplinary training program for talented young researchers, to prepare them for leading roles in chronic liver disease research. Dr Fabregat has published around 130 articles in indexed journals, as well as several book chapters, with her work published in <i>Hepatology</i>, <i>Journal of Hepatology</i>, <i>Genes & Development</i>, <i>Cancer Research</i>, <i>Oncogene</i>, <i>FASEB Journal</i>, <i>Free Radical in Biology & Medicine</i>, <i>Journal of Cell Science</i>, <i>Journal of Biological Chemistry</i>, among others. She is an editorial member of the <i>World Journal of Gastroenterology</i>, <i>World Journal of Hepatology</i>, <i>Frontiers in Physiology-Gastrointestinal Sciences</i>, <i>Frontiers in Pharmacology</i>, <i>Current Signal Transduction Therapy</i> and <i>Hepatic Oncology</i>.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 1","pages":"9-13"},"PeriodicalIF":5.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrotransposons and genetic instability in hepatocellular carcinoma.","authors":"Ruchi Shukla","doi":"10.2217/hep-2017-0010","DOIUrl":"https://doi.org/10.2217/hep-2017-0010","url":null,"abstract":"","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 1","pages":"5-8"},"PeriodicalIF":5.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When to consider liver transplantation in hepatocellular carcinoma patients?","authors":"Ka Wing Ma, Tan To Cheung","doi":"10.2217/hep-2016-0010","DOIUrl":"10.2217/hep-2016-0010","url":null,"abstract":"<p><p>Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"4 1","pages":"15-24"},"PeriodicalIF":5.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095144/pdf/hep-04-15.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The next generation of hepatocellular cancer experts: what do they think?","authors":"Shahid A Khan,&nbsp;Stephen McClements,&nbsp;Isabella Reccia,&nbsp;Joanne Evans,&nbsp;Madhava Pai,&nbsp;Rohini Sharma","doi":"10.2217/hep-2017-0003","DOIUrl":"https://doi.org/10.2217/hep-2017-0003","url":null,"abstract":"Imperial College London/Imperial College Healthcare NHS Trust, London, UK St Mary’s Hospital Campus, Department of Surgery and Cancer, Imperial College London/ImperialCollege Healthcare NHS Trust, London, UK *Author for correspondence: Tel.: +44 203 312 6454/6254; Fax: +44 207 724 9369; shahid.khan@imperial.ac.uk","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 4","pages":"213-215"},"PeriodicalIF":5.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2017-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}